- Elanco Animal Health (ELAN, Financial) exceeded its innovation revenue target with $461 million in 2024.
- Ranked as the #1 retail parasiticide dispenser in the U.S.
- Employee engagement improved to 71% in Q1 2025, a 4% increase year-over-year.
Elanco Animal Health Incorporated (ELAN) has unveiled its 2024 Impact Report, marking significant advancements across its operational domains. Focusing on animals, customers, society, and employees, Elanco's new framework drives innovation and impact.
In 2024, Elanco achieved $461 million in innovation revenue, surpassing its anticipated range of $420-$450 million, thanks to the successful market introduction of products such as Zenrelia, Credelio Quattro, and Pradalex. This positioned Elanco as the leading retail parasiticide distributor in the U.S.
The company's commitment to environmental sustainability was emphasized by the launch of Bovaer®, a groundbreaking methane-reducing feed additive for dairy cattle. In addition, 11% of the U.S. dairy herd has been enrolled in Elanco's UpLook sustainability platform, enabling farmers to generate approximately $10 million in carbon credits.
Elanco's societal contributions were substantial, with $400,000 in product donations and 26,000 volunteer hours. The firm also reported a 71% employee engagement score in Q1 2025, reflecting a 4% improvement from the previous year, signifying enhanced workforce satisfaction and collaboration.
The report highlights the strategic use of partnerships, such as with Medgene, to innovate in vaccine technology and product transparency, reinforcing Elanco's dedication to its core mission of "Going Beyond" for all stakeholders.
